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Metabolomic studies show that rheumatoid arthritis (RA) is associated with
metabolic disruption that may be therapeutically targetable. Among them, glucose
metabolism and glycolytic intermediaries seem to have an important role in
fibroblast-like synoviocytes (FLS) phenotype and might contribute to early stage
disease pathogenesis. RA FLS are transformed from quiescent to aggressive and
metabolically active cells and several works have shown that glucose metabolism
is increased in activated FLS. Glycolytic inhibitors reduce not only FLS aggressive
phenotype in vitro but also decrease bone and cartilage damage in several murine
models of arthritis. Essential glycolytic enzymes, including hexokinase 2 (HK2)
and 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase (PFKFB) enzymes, have
important roles in FLS behavior. Of interest, HK2 is an inducible enzyme present only
in the inflamed rheumatic tissues compared to osteoarthritis synovium. It is a contributor
to glucose metabolism that could be selectively targeted without compromising systemic
homeostasis as a novel approach for combination therapy independent of systemic
immunosuppression. More information about metabolic targets that do not compromise
global glucose metabolism in normal cells is needed.
Keywords: rheumatoid arthritis, fibroblast-like synoviocytes, hexokinase-2, glucose metabolism, glycolytic
inhibitors
Rheumatoid arthritis (RA) pathogenesis includes synovial hyperplasia or pannus, which consists of
accumulation of macrophages and fibroblast like synoviocytes (FLS) (1–4), resulting in enhanced
invasiveness and destruction of adjacent cartilage and bone (3, 5). FLS are the major component of
rheumatoid pannus and have a key role in its formation (4). In healthy individuals, these cells ensure
the structural integrity of a normally organized synovial lining (6) and secretes hyaluronic acid
and lubricin, two important constituents of synovial fluid that are responsible for lubricating the
joint (7, 8). However, after acquiring an aggressive phenotype, FLS have reduced contact inhibition,
resistance to apoptosis, increased migration, and increased ability to invade periarticular tissues
including bone and cartilage (4, 9). These activated cells produce several mediators that induce
angiogenesis, cell growth, and recruitment and activation of immune cells (4). In addition to
contributing to the inflammatory environment, FLS also produce matrix metalloproteases (MMPs)
that degrade the extracellular matrix and contributes to cartilage destruction (10).
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Recently, an increasing number of studies have shown that
FLS activation and the subsequent joint damage are associated
with an altered metabolism which may be therapeutically
targetable. The metabolism of all four major classes of
macromolecules (carbohydrates, proteins, lipids, and nucleic
acids) will change after cell activation. Carbohydrate metabolism
is a fundamental biochemical process that ensures a constant
supply of energy to living cells. The most important carbohydrate
is glucose, which is first transported into the cell through
glucose transporter 1 (GLUT1), then broken down via glycolysis
by sequential metabolic enzymes [including hexokinase (HK),
aldolase, phosphoglycerate kinase (PGK1), and pyruvate kinase]
to generate pyruvate, and afterwards will either enter into the
tricarboxylic acid (TCA) cycle and oxidative phosphorylation
to generate ATP, or will be converted to lactate via lactate
dehydrogenase (LDH).
Activation of FLS by hypoxia, platelet-derived growth factor
(PDGF), tumor necrosis factor (TNF), and other inflammatory
mediators increases glucose metabolism and transforms the
FLS from quiescent to aggressive and metabolically active
cells. Specifically, prior work—ours and others—has shown
that glucose metabolism is increased in activated FLS, and
glycolytic inhibition reduces not only FLS aggressive phenotype
in vitro but also decreases bone and cartilage damage in several
murine models of arthritis [(11–13); Table 1]. These works have
suggested potential metabolic targets to reprogram metabolic
disruptions and complement current therapies (11–13). In this
brief review, we will summarize what is known about glucose
metabolism in FLS and about potential metabolic therapies for
RA that could modulate the aggressive behavior of FLS.
GLUCOSE METABOLISM ACTIVATION IN
THE RA FLS
Glucose metabolism seems to be especially enhanced in
joints with arthritis and involved in RA pathology. The high
consumption of glucose by the RA joints can be visualized by PET
imaging with 18F-FDG, a probe that detects glycolytic tissues
(25). Synovial FLS and macrophages were shown to contribute
to FDG-PET accumulation in the RA synovial tissue (26). The
synovial tissue of RA patients also presents an enhanced level
of lactate compared to non-inflamed synovial tissue (27). The
local lower glucose levels and higher ratio of lactate to glucose
in the RA synovial tissue suggest an increase in anaerobic cellular
metabolism of resident cells, triggered by the inflammation and
the hypoxic environment commonly detected in the RA joints
(28, 29). This dysregulation is further suggested by the increase of
lactate and glucose in the serum of RA patients (30). Moreover,
glucose levels are lower in the synovial fluid of RA patients
in comparison to non-inflamed synovial fluid (31). This is also
supported by metabolic studies using mass spectrometry, which
show differential metabolite profile in RA FLS and osteoarthritis
(OA) FLS (32). Glycolysis, pentose phosphate pathway (PPP),
and amino acid metabolism were different in RA FLS compared
to OA FLS (32). In addition, FLS increased its intracellular levels
of glucose after TNF stimulation (33).
Shift from oxidative phosphorylation to glycolytic ATP
production is a common feature of activated and reactive cells
like fibroblasts and macrophages. Micro environmental factors
in the RA joint seem to potentiate this metabolic adaptation
of FLS and macrophages. The synovial tissue is enriched
in hypoxia-inducible factor 1 alpha (HIF1α), a transcription
factor induced in hypoxic environments that contributes to
RA pathogenesis at multiple steps (29), including supporting
enhanced glycolytic activity. Among the HIF1α-transcriptionally
regulated glucose metabolism related genes, GLUT1, HK2, and
LDH are upregulated in RA FLS (14, 19, 34–36). The effect of
HIF1α on glycolysis contributes to FLS survival (37), myeloid
recruitment by FLS, angiogenesis (38), and FLS migration and
invasion (29). In addition, it promotes the expression in RA
FLS of inflammatorymediators that perpetuates interactions with
other synovial cells including T and B cells (39, 40).
Other signaling pathways critical for FLS expression of
adhesion molecules, pro-inflammatory cytokines, and MMPs,
as well as for apoptosis inhibition, and for FLS migration
and invasion are mitogen-activated protein kinases (MAPK),
nuclear factor kappa B (NF-κB), and phosphoinositide-3-
kinase (PI3K)/AKT (41–50). These pathways are activated
by both hypoxia and inflammation. They also regulate
glucose metabolism through several mechanisms including
the upregulation of GLUT1 (51). These pathways are also
involved in the phosphorylation of rate-limiting glycolytic
enzymes, including 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatases (PFKFB) and HKs (52, 53). JAK/STAT
signaling, which also plays a role in FLS activation (54–56),
was also shown to mediate glucose uptake and HK2 expression
(57). Therefore, the phenotypic changes from FLS at rest to
an activated and invasive state are coupled with metabolic
alterations like increased GLUT1 and HK2 expression and
lactate production (14, 17).
Likewise, the inhibition of glycolysis decreases the aggressive
behavior of these cells by decreasing cytokine production,
proliferation, migration, and invasion (14, 17). Three targetable
glycolytic enzymes were recently shown to be involved in
FLS aggressive phenotype. One is the bifunctional PFKFB3
enzyme, which converts fructose-6-phosphate to fructose-
2,6-bisP (F2,6BP). F2,6BP is an allosteric activator of
6-phosphofructokinase-1 (PFK-1) and stimulates glycolysis
overriding the inhibitory effect of ATP on PFK-1 (58). It was
identified as a regulator of insulin/IGF-1 signaling pathway.
Suppression of PFKFB3 was found to decrease insulin-stimulated
glucose uptake, GLUT4 translocation, Akt signaling, and
glycolytic flux (59). In FLS, PFKFB3 inhibition reduced glucose
uptake which resulted in decreased lactate production (17, 18).
The inhibition of the glycolytic flux by small molecule inhibitors
of PFKFB3 significantly reduced FLS migration and invasion,
and the production of inflammatory mediators (17). Of interest,
FPFK15, a PFKFB3 inhibitor, not only suppressed glucose uptake
and lactate secretion but also NF-κB andMAPK activation in RA
FLS (18). The second enzyme is the rate-limiting enzyme HK2.
Overexpression of HK2 in FLS provides a migratory and invasive
advantage that is abolished when HK2 is ablated (19, 20). The
last enzyme is phosphoglycerate kinase (PGK)1. Anti-PGK1
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TABLE 1 | Glycolyitic intermediate metabolites and their effect on RA FLS and animal models of arthritis.
Intermediate Enzyme Trigger response References
Glucose Glucose deprivation decreased IL-6, MMP-1 and MPP-3
production and the rate of proliferation and migration of FLS. In
the SKG mouse model of arthritis, the glucose analog 2-DG
decreased clinical score and thickness
(14, 15)
Fructose 1,6-bisphosphate FBP1 Treatment with fructose 1,6-biphosphate reduced MPO activity,
IL-6 and TNF-α joint levels, nociception, and neutrophil migration
to the joint of mice with ZIA and AIA
(16)
Fructose 2,6-bisphosphate PFKFB3 Inhibition of fructose 2,6-bisphosphate production decreased
IL-6 secretion and proliferation, migration and invasion of FLS
(17, 18)
Glucose-6-phosphate
1,3-bisphosphoglycerate/
3-phosphoglycerate
HK2
PGK1
HK2 ablation decreased FLS invasive phenotype and also
attenuated the severity of bone and cartilage damage in a mouse
model of inflammatory arthritis
Silencing of PGK1 decreased the secretion of IL-1β and IFN-γ as
well as proliferation of FLS
(19–21)
Pyruvate Use of BrPa (a halogenated analog of pyruvate that inhibits
glycolysis) decreased histologic score and levels of arthritis in
K/BxN mouse models of arthritis
(14, 15, 20, 22)
Lactate LDH/MCT Increased levels of lactate induced FLS invasiveness (17)
Succinate SDH Succinate induced fibrosis and angiogenesis and SDH inhibition
attenuated the severity of rat CIA
(23, 24)
FLS, fibroblast-like synoviocyte; FBP1, fructose 1,6-biphosphatase; 2-DG, 2-deoxy-D-glucose; MPO, myeloperoxidase; ZIA, zymosan-induced arthritis; AIA, antigen-induced arthritis;
PGK1, phosphoglycerate kinase 1; BrPa, bromopyruvate; MCT, monocarboxylate transporters.
siRNA treatment of RA FLS not only decreased cell proliferation
and cell migration, but also interleukin (IL)-1β and interferon
(IFN)-γ secretion (21).
Since metabolic pathways are highly interconnected, other
metabolic pathways described in activated FLS might also affect
global glucose metabolism. Glutamine metabolism is increased
in FLS, with glutaminase 1 (GLS1) playing a role in regulating
the proliferation of these cells. FLS proliferation is reduced
under glutamine-deprived conditions, or after GLS1 silencing or
inhibition (60). Choline metabolism is also highly activated in
FLS. Inhibition of choline kinase (ChoKα) suppressed the RA FLS
aggressive phenotype by increasing apoptosis and decreasing cell
migration (61). Glycogen synthase 1 (GYS1)-mediated glycogen
accumulation was shown to block AMPK activation and to
contribute to FLS phenotype as well (62). Finally, RA FLS
also overexpresses the neutral amino acid transporter LAT1,
and has an increased uptake of leucine after IL-17 stimulation,
which potentiate FLS migratory capacity that was eliminated by
blocking LAT1 (63). Other amino acids including tryptophan
might also play a role in FLS phenotype (64).
FLS GLUCOSE METABOLISM AND
CHRONIC ACTIVATION IN RA
Although researchers have suggested a role for metabolic
alterations in RA pathology, we are far from understanding which
changes are normal responses to cell activation and are transient
metabolic responses to acute inflammation, and which are the
result of damage and chronic activation that could play a role in
driving the pathology of RA. These chronic metabolic changes in
FLS can have not only profound effects on the biology of other
cells through intermediate metabolites but also can create a new
epigenetic landscape that results in a stable FLS activation that is
maintained even without continuous stimulation (Figure 1A).
Some pro-inflammatory mediators increase several TCA
cycle intermediates, and emerging evidence show that these
intermediates classically associated with metabolic functions
also possess signaling functions as inflammatory mediators
and drive chronic activation. For instance, metabolic profiling
has revealed itaconic acid as a potential marker of RA,
and TNF increased its concentration in the K4IM human
fibroblast cell line (65). Importantly, the increased levels in
itaconic acid can be attenuated by treatment with infliximab,
a biologic drug targeting TNF (65). Succinate is another
TCA cycle intermediate that is abundant in RA synovial
fluids. Synovial succinate correlates with enhanced release of
IL-1β by macrophages in a mechanism that involves the
overexpression of succinate receptor Sucnr1/GPR91 (66). In
addition, Sucnr1/GPR91 functions as a chemotactic signal for
recruitment of dendritic cells into lymph nodes which leads
to Th17 cells expansion in a murine model of inflammatory
arthritis (67). In FLS, succinate has a myofibroblast effect on
FLS (23). A recent paper also evaluated Sucnr1/GPR91 in FLS
and concluded that both intra- and extracellular succinate play
a role in synovial angiogenesis. Intracellular succinate induced
angiogenesis through HIF1α induction, while extracellular
succinate increased vascular endothelial growth factor (VEGF)
through GPR91 receptor (24).
Pyruvate is another metabolite generated during glycolysis
and is converted to acetyl-CoA to fuel the TCA cycle. Acetyl-
CoA is an important cofactor that catalyzes the transfer of an
acetyl group. Histone acetyltransferases (HATs) are enzymes
that use this co-factor and regulate histone acetylation and
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FIGURE 1 | Fibroblasts-like synoviocytes (FLS) glucose metabolism and chronic activation in RA. (A) Chronic glucose metabolic changes induced by hypoxia
and inflammatory mediators in FLS will activate many signaling pathways, including HIF, MAPK, PI3K/Akt, and JAK/STAT pathways, which also increases the
expression of key glucose metabolism related genes such as GLUT1, HK2, or LDH. Intermediate glucose metabolites including pyruvate, lactate, succinate,
a-ketoglutarate, fumarate, and acetyl-coenzyme will create a chronic and sustained FLS activation, either by being secreted extracellularly and triggering profound
effects on the biology of other cells, or by inducing a new epigenetic landscape that results in a stable FLS activation that is maintained even without continuous
stimulation. (B) Hypoxia, growth factors, and cytokines in arthritis synovium stimulate Akt phosphorylation, which will up-regulate HK2 expression and HK2
phosphorylation. The phosphorylation of HK2 by Akt is accompanied by an increased binding of the enzyme to mitochondrial outer membrane voltage-dependent
anion channel (VDAC). Binding to VDAC enhances the affinity of hexokinases. Therefore, HK2 mitochondrial binding might promote glucose metabolism and FLS
invasive phenotype. Mitochondrial HK2 might also inhibit apoptosis. Thus, mitochondrial association of HK2 might promote resistance to growth, invasion, and
apoptosis of RA FLS, which contribute to joint destruction in RA. Selective HK2 mitochondrial dissociation might be an attractive potential selective target for arthritis
therapy and safer than global glycolysis inhibition. HK2, hexokinase 2; G6PD, glucose 6 phosphate dehydrogenase; PKM2, pyruvate kinase muscle isozyme M2; PFK,
phosphofructokinase; PFKB3, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3; G6P, glucose-6-phosphate; F6P, fructose-6-phosphate; F1,6BP, Fructose
1,6-bisphosphate; F2,6FB, Fructose 2,6-bisphosphate; VDAC: voltage-dependent anion channel.
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therefore link metabolism and epigenetics in cells (68, 69).
Other metabolites elevated after glucose metabolism activation
such as fumarate, succinate, and lactate also modify chromatin
and nucleic acid-modifying enzymes activity by competitively
inhibiting substrate utilization (68). The relationship between
metabolic intermediates and chromatin-modifying enzymes
implies that metabolic changes could directly affect gene
expression by modulating chromatin-modifying enzymes and
triggering epigenetic dysfunction (68, 69). Of interest, several
reports have shown that epigenetic alterations, such as histone
modification, might contribute to RA pathogenesis (70). In
fact, a comprehensive epigenomic characterization of RA FLS
has recently been described (71), suggesting that synovial
fibroblasts stimulation results in a stable activation that
is maintained even without continuous stimulation through
epigenetic changes. Further FLS studies are needed to better
understand the epigenetic modifications affecting metabolic
gene expression and glucose metabolism that can drive
chronic RA FLS activation and may help to identify novel
metabolic targets.
GLUCOSE METABOLISM TARGETS IN RA
FLS
The concept of metabolic reprogramming to improve
immunotherapy and to complement current therapies is
being slowly translated into the autoimmune disease field
(11, 72–74). In fact, glycolytic inhibitors not only reduce FLS
aggressive phenotype in vitro but also decrease bone and
cartilage damage in several murine models of arthritis. More
specifically, ablation of glycolytic genes or treatment with
3-bromopyruvate, which antagonizes HK2, significantly reduced
the severity of several murine arthritis models (14, 15, 19, 20, 22).
Although HK2 specific inhibitors are not available, HK2 can
be inhibited by the use of 2-deoxyglucose (2-DG), which is a
derivative of glucose that can be phosphorylated by HK2 but
not mobilized through succeeding steps of glycolysis. Murine
studies have shown that 2-DG reduces cell proliferation and
the severity of a spontaneous model of RA arthritis (15). HK2
ablation has also attenuated the severity of bone and cartilage
damage in a murine model of inflammatory arthritis (19).
Interestingly, the administration of fructose 1,6-bisphosphate
(FBP), a glycolytic intermediate, decreased arthritis scores in
two different animal models. Mechanistic studies showed that
this metabolic intermediate activated the anti-inflammatory
adenosinergic pathway instead of enhancing FLS glycolysis (16).
Treatment with a saponin that inhibits succinate dehydrogenase
(SDH) activity ameliorated the clinical symptoms of the arthritis
as well as histopathologic features of synovial hyperplasia,
infiltration of inflammatory cells, and fibrosis (23). In addition,
treatment with dimethylmalonate, another inhibitor of SDH,
decreased succinate content in the synovial tissue of rats with
collagen-induced arthritis (CIA) in addition to amelioration of
the disease (24). Finally, inhibition of the enzyme ChoKα (61)
and GLS1 (62) also ameliorated the severity of experimental
autoimmune arthritis.
Yet, although all these works have demonstrated a role of
glucose metabolism in RA, inhibiting global glucose metabolism
is not desirable. In addition, inhibition of some of the above
pathways can have other detrimental effects. For instance, a
recent report demonstrated a key anti-inflammatory function
of HIF1α by driving the expression of IL-10 in B cells (75).
PFKFB3 activity is also defective in CD4T cells in RA patients
which results in energy deprivation that prone cells to undergo
apoptosis (76). Thus, there is a need of finding specific metabolic
targets that are induced in activated FLS.
Out of all the glycolytic enzymes described to play a role in
RA pathogenesis, HK2 could function as a selective metabolic
target (Figure 1B). HKs catalyze the phosphorylation of glucose
to glucose-6-phosphate (G6P) that facilitates glucose entry
into cells. G6P initiates several metabolic pathways that need
glucose, including glycolysis, the hexosamine pathway, glycogen
synthesis, and the PPP (77). HK2 also plays important roles
in angiogenesis (78). HKs has four different isoforms: HK1 is
the ubiquitous isoform in all adult issues. However, HK2 is an
inducible isoform that is only highly expressed in skeletal and
cardiac muscles, and adipose tissue (77). HK2 is also highly
upregulated in tumor cells and HK2 inhibition synergies with
anti-tumor treatment and improves response to therapy (79).
In addition to its canonical metabolic roles in tumor or cardiac
tissues, HK2 translocates to the nucleus or mitochondria and
triggers an autophagic and anti-apoptotic responses through its
interaction with the voltage-dependent anion channel (VDAC)
(80, 81). Of interest, HK2 plays a small role in inflammation
driven by T cells, so HK2 inhibition should have limited
immunosuppressive effects (82). Importantly, we and others have
shown that the synovial expression of HK2 is elevated only in
RA compared to OA samples (19, 20). Given HK2 selective
overexpression in inflamed RA synovium, its small role in T
cells, and its expression in a very limited number of adult
tissues, HK2 is an attractive selective target for arthritis therapy
that is safer than global glucose metabolism inhibition (19). In
addition to its expression profile, its diverse effects at various
cellular compartments could offer another level of specificity
since targeting a specific intracellular compartment of HK2
(i.e., cytosol, nucleus, or mitochondria) would also provide a
selective means to block deleterious effects of this enzyme in RA
without affecting glucose metabolism in normal cells. Therefore,
HK2 could be selectively targeted offering a safer and novel
additional approach for combination therapy in RA joint disease
independent of systemic immunosuppression.
Of interest, rheumatologists already have antimetabolites
in the current RA armamentarium, such as methotrexate
and leflunomide. Although they were thought to inhibit the
proliferation of synovial and immune cells, methotrexate and
other disease-modifying antirheumatic drugs (DMARDs)
also have effect on glucose metabolism. For instance,
methotrexate treatment significantly reduced HK2 expression
and glucose/fructose carriers (SLC2A5, a member of the solute
carrier family 2) in human FLS, suggesting that FLS glycolytic
activity can be modulated by methotrexate (83). Anti-TNF
treatment decreases the synovial expression of GLUT1 and of the
glycolytic enzymes pyruvate kinase muscle isozyme M2 (PKM2)
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and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in
patients that responded to TNF inhibition compared to non-
responders (17). Anti-IL-6 receptor therapy inhibited oxidative
stress and improved endothelial function in RA leucocytes,
although whether or not this therapy also has a metabolic effect
on the synovial tissue is not known yet (84). Finally, inhibition of
JAK/STAT3 signaling with tofacinib, a drug approved for severe
RA and active psoriasis, induces oxidative phosphorylation
and maximal respiratory capacity of FLS while shutting down
key glycolytic enzymes including HK2 and LDH. This effect
correlated with the reduction of inflammatory mediators and
FLS activation (85).
CONCLUSION
Growing evidence suggests that the study of activatedmetabolism
not only of immune cells but also of stroma cells including
FLS can provide critical pathways for therapeutic intervention.
Pre-clinical studies in mouse models of inflammatory arthritis
strongly suggest that agents that interfere with certain steps of
glycolysis can be therapeutic in RA and have identified potential
targetable glycolytic enzymes such as HK2, and glycolytic
intermediate metabolites (Table 1). In addition, therapeutic
effects of DMARDs could be due, at least partially, to the
inhibition of glucose metabolism, highlighting the pathogenic
role of this metabolic pathway. As global inhibition of glucose
metabolism is not desirable, more information about inducible
glycolytic genes, the specific distribution of these targets, their
effect in different cellular compartments, and their additional
non-metabolic functions, may help us to identify new targets that
do not compromise global glucose metabolism in normal cells.
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